scholarly journals Radiotherapy in Inoperable Mucoepidermoid Parotid Cancer: A Case Report

2021 ◽  
Vol 15 (2) ◽  
pp. 95
Author(s):  
Steven Octavianus ◽  
Henry Kodrat
Keyword(s):  
Salivary Gland ◽  
Mucoepidermoid Carcinoma ◽  
Postoperative Radiotherapy ◽  
Salivary Gland Cancer ◽  
Case Presentation ◽  
Tumor Mass ◽  
Definitive Radiotherapy ◽  
Salivary Gland Malignancy ◽  
Clinical Benefits ◽  
The Right

Introduction: Salivary gland cancer is an uncommon malignancy in the head and neck. The most common histopathologic type in salivary gland malignancies is mucoepidermoid carcinoma (MEC). Radiotherapy has a role in salivary gland malignancy, especially in inoperable cases and postoperative settings. Definitive or postoperative radiotherapy with or without chemotherapy can improve locoregional control (LRC) in patients with parotid mucoepidermoid carcinoma. Case Presentation: We report a case of a 77-year-old male with inoperable MEC of the right parotid, who received definitive radiotherapy. From the three-month evaluation after radiation therapy, we found a significant reduction in the tumor mass. Conclusions: Surgery remains the treatment of choice for patients with salivary gland malignancies. Definitive radiotherapy can be a treatment modality in inoperable cases or patients who refuse surgery. Although the result is not satisfactory, radiotherapy can still give clinical benefits to patients.

scholarly journals Mucoepidermoid Carcinoma of the Palatine Tonsil

2015 ◽  
Vol 2015 ◽  
pp. 1-6
Author(s):  
Lucas Novaes Teixeira ◽  
Victor Angelo Martins Montalli ◽  
Luiz Carlos Santana Teixeira ◽  
Fabrício Passador-Santos ◽  
Andresa Borges Soares ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Oral Cavity ◽  
Mucoepidermoid Carcinoma ◽  
Unusual Case ◽  
Cell Types ◽  
Palatine Tonsil ◽  
Soft Mass ◽  
Salivary Gland Malignancy ◽  
Adults And Children ◽  
Intermediate Cells

Mucoepidermoid carcinoma (MEC) is the most common primary salivary gland malignancy in both adults and children. It has a slight female predilection and usually presents as a painless, rubber-like or soft mass, which may be fixed or mobile. Histologically, MEC is comprised of a mixture of cell types including mucous, epidermoid, and intermediate cells that can be arranged in solid nests or cystic structures. In the oral cavity, it most frequently occurs at the palate or buccal mucosa. The present paper aimed to describe an unusual case of MEC arising in the palatine tonsil.

scholarly journals Metastasis of hepatocellular carcinoma presented as a tumor of the maxillary sinus and retrobulbar tumor

2011 ◽  
Vol 68 (4) ◽  
pp. 359-362 ◽  
Author(s):  
Daniela Kolarevic ◽  
Zorica Tomasevic ◽  
Ivan Boricic ◽  
Dejan Rasic ◽  
Natasa Andjelic-Dekic ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lymph Nodes ◽  
Maxillary Sinus ◽  
Poor Prognosis ◽  
Postoperative Radiotherapy ◽  
Extrahepatic Metastasis ◽  
Histopathological Analysis ◽  
Dental Surgery ◽  
Tumor Mass ◽  
The Right

Introduction. Hepatocellular carcinoma (HCC) is the most frequent primary malignant tumor of the liver. It is usually seen in the 6th and 7th decades of life and chronic hepatitis B is the most frequent cause. Extrahepatic metastasis of HCC is an indicator of a poor prognosis and the most common sites are lungs, bones, lymph nodes, kidneys and adrenal glands. We reported a case of isolated metastasis in the right maxilla, which had been found initially, before the tumor in the liver was diagnosed. Case report. A 70-year-old man underwent dental surgery of the upper right molar. Prolonged bleeding control was difficult for up to two weeks, so the biopsy was performed. Histopathological analysis revealed a metastatic hepatocellular carcinoma. Computerized tomography (CT) of the abdomen revealed a diffusely heterogeneous liver parenchyma with irregular borders and two foci of mass lesions. There were metastasis in the spleen and also two pathological retroperitoneal lymph nodes were detected, but no ascit, liver cirrhosis, cholestasis or portal vein thrombosis were seen. CT of the orbital and maxillary regions revealed a tumor mass in the right maxillary sinus, spreading to the alveolar sinus, nasal cavity and partially infratemporal space. A tumor mass was in the right orbit as well, infiltrating the surrounding bones and muscles. Clinically, there was proptosis of the right eye accompanied by amaurosis. The treatment started with chemotherapy based on 5-fluorouracil (sorafenib was not available). After three cycles, control CTs showed a stable disease in the liver, but progression in the right maxillary sinus and orbit. Enucleation of the right eye was performed and postoperative radiotherapy was planed. The patient deteriorated rapidly and died, about 6 months after the disease had been diagnosed. Conclusion. Extrahepatic metastasis of HCC represents a progressive phase of the disease with poor prognosis, so the main aim of the treatment should be palliation and care of symptoms.

Isolated mucoepidermoid carcinoma in the neck

1998 ◽  
Vol 119 (4) ◽  
pp. 398-399 ◽  
Author(s):  
Manish K. Wani ◽  
K. Thomas Robbins ◽  
Frank S. H. Wong ◽  
Todd E. Stiles
Keyword(s):  
Salivary Gland ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Mucoepidermoid Carcinoma ◽  
Cervical Lymph Node ◽  
Common Type ◽  
Primary Site ◽  
Cervical Lymph Nodes ◽  
Salivary Gland Malignancy

Mucoepidermoid carcinoma is a common type of salivary gland malignancy with metastasis to the cervical lymph nodes occurring in up to 29% of patients. 1 We describe three patients presenting with isolated mucoepidermoid carcinoma in a cervical lymph node without an obvious primary site of origin.

scholarly journals Survival of salivary gland cancer stem cells requires mTOR signaling

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Nathalia P. Andrade ◽  
Kristy A. Warner ◽  
Zhaocheng Zhang ◽  
Alexander T. Pearson ◽  
Andrea Mantesso ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Tumor Cells ◽  
Mucoepidermoid Carcinoma ◽  
Therapeutic Potential ◽  
Mtor Pathway ◽  
Mtor Signaling ◽  
Salivary Gland Cancer ◽  
Self Renewal ◽  
Immunodeficient Mice

AbstractAdvanced salivary gland mucoepidermoid carcinoma (MEC) is a relentless cancer that exhibits resistance to conventional chemotherapy. As such, treatment for patients with advanced MEC is tipically radical surgery and radiotherapy. Facial disfigurement and poor quality of life are frequent treatment challenges, and many patients succumb to loco-regional recurrence and/or metastasis. We know that cancer stem-like cells (CSC) drive MEC tumorigenesis. The current study tests the hypothesis that MEC CSC are sensitive to therapeutic inhibition of mTOR. Here, we report a correlation between the long-term clinical outcomes of 17 MEC patients and the intratumoral expression of p-mTOR (p = 0.00294) and p-S6K1 (p = 0.00357). In vitro, we observed that MEC CSC exhibit constitutive activation of the mTOR signaling pathway (i.e., mTOR, AKT, and S6K1), unveiling a potential strategy for targeted ablation of these cells. Using a panel of inhibitors of the mTOR pathway, i.e., rapamycin and temsirolimus (mTOR inhibitors), buparlisib and LY294002 (AKT inhibitors), and PF4708671 (S6K1 inhibitor), we observed consistently dose-dependent decrease in the fraction of CSC, as well as inhibition of secondary sphere formation and self-renewal in three human MEC cell lines (UM-HMC-1,-3A,-3B). Notably, therapeutic inhibition of mTOR with rapamycin or temsirolimus induced preferential apoptosis of CSC, when compared to bulk tumor cells. In contrast, conventional chemotherapeutic drugs (cisplatin, paclitaxel) induced preferential apoptosis of bulk tumor cells and accumulation of CSC. In vivo, therapeutic inhibition of mTOR with temsirolimus caused ablation of CSC and downregulation of Bmi-1 expression (major inducer of stem cell self-renewal) in MEC xenografts. Transplantation of MEC cells genetically silenced for mTOR into immunodeficient mice corroborated the results obtained with temsirolimus. Collectively, these data demonstrated that mTOR signaling is required for CSC survival, and unveiled the therapeutic potential of targeting the mTOR pathway for elimination of highly tumorigenic cancer stem-like cells in salivary gland mucoepidermoid carcinoma.

scholarly journals Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection

2019 ◽  
Vol 160 (6) ◽  
pp. 1048-1057 ◽  
Author(s):  
Katri Aro ◽  
Allen S. Ho ◽  
Michael Luu ◽  
Sungjin Kim ◽  
Mourad Tighiouart ◽  
...  
Keyword(s):  
Overall Survival ◽  
Salivary Gland ◽  
Neck Dissection ◽  
Proportional Hazards ◽  
Postoperative Radiotherapy ◽  
Multivariable Analysis ◽  
Salivary Gland Cancer ◽  
National Cancer Database ◽  
Curative Intent ◽  
The Impact

Objective To evaluate the impact of postoperative radiotherapy (PORT) and chemotherapy on survival in salivary gland cancer (SGC) treated with curative-intent local resection and neck dissection. Study Design Retrospective population-based cohort study. Setting National Cancer Database. Subjects and Methods Patients with SGC who were undergoing surgery were identified from the National Cancer Database between 2004 and 2013. Neck dissection removing a minimum of 10 lymph nodes was required. Because PORT violated the proportional hazards assumption, this variable was treated as a time-dependent covariate. Results Overall, 4145 cases met inclusion criteria (median follow-up, 54 months). PORT was associated with improved overall survival in multivariable analysis, both ≤9 months from diagnosis (hazard ratio [HR], 0.26; 95% CI, 0.20-0.34; P < .001) and >9 months (HR, 0.75; 95% CI, 0.66-0.86; P < .001). In propensity score–matched cohorts, 5-year overall survival was 67.1% and 60.6% with PORT and observation, respectively ( P < .001). Similar results were observed in landmark analysis of patients surviving at least 6 months following diagnosis. Adjuvant chemotherapy was not associated with improved survival (HR, 1.15; 95% CI, 0.99-1.34; P = .06). Conclusion PORT, but not chemotherapy, is associated with improved survival among patients with SGC for whom neck dissection was deemed necessary. These results are not applicable to low-risk SGCs not requiring neck dissection.

mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells

2020 ◽  
pp. 002203452096514
Author(s):  
T. Nakano ◽  
K.A. Warner ◽  
A.E. Oklejas ◽  
Z. Zhang ◽  
C. Rodriguez-Ramirez ◽  
...  
Keyword(s):  
Stem Cells ◽  
Salivary Gland ◽  
Cancer Stem Cells ◽  
Mucoepidermoid Carcinoma ◽  
Salivary Gland Cancer ◽  
Mtor Inhibition ◽  
Platinum Based Chemotherapy ◽  
The Impact

Patients with advanced salivary gland mucoepidermoid carcinoma (MEC) are treated with surgery and radiotherapy, as current systemic therapies are largely ineffective. As such, current treatment frequently leads to poor long-term survival due to locoregional recurrence or metastases. We have shown that salivary gland cancer stem cells (CSCs) are resistant to platinum-based chemotherapy and drive tumor progression. The purpose of this study was to investigate the effect of therapeutic inhibition of mTOR (mechanistic target of rapamycin) on resistance of CSCs to cisplatin, a prototypic platinum-based chemotherapeutic agent. Viability assays determined the effect of several inhibitors of PI3k/mTOR signaling (e.g., temsirolimus, BKM120, AZD8055, PF4708671) and/or cisplatin on survival of human MEC cells. The impact of mTOR inhibitors and/or cisplatin on MEC stemness was examined with salisphere assays, flow cytometry for ALDH/CD44 (CSC markers for MEC), and Western blots for Bmi-1 expression (marker of stem cell self-renewal). Salivary gland MEC patient-derived xenografts were used to examine the effect of cisplatin and/or temsirolimus on CSCs in vivo. We observed that cisplatin induced mTOR and S6K1 phosphorylation, increased the number and size of MEC salispheres, and induced Bmi-1 expression and the fraction of CSCs in MEC models in vitro. Cisplatin also increased the fraction of CSCs in vivo. In contrast, mTOR inhibition (e.g., temsirolimus) blocked cisplatin-induced Bmi-1 expression and salisphere formation in vitro. Remarkably, temsirolimus slowed down tumor growth and decreased the fraction of CSCs ( P < 0.05) even in presence of cisplatin in a short-term in vivo experiment. Collectively, these results demonstrate that therapeutic inhibition of mTOR ablates cytotoxic-resistant CSCs, and they suggest that a combination of an mTOR inhibitor and platinum-based chemotherapy might be beneficial to patients with salivary gland mucoepidermoid carcinoma.

scholarly journals A case report of bronchial pleomorphic adenoma in a child in China

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Haiqin Zhong ◽  
Silei Yan ◽  
Kung Jiang ◽  
Yijing Hu ◽  
Xiaoyan Dong
Keyword(s):  
Computed Tomography ◽  
Salivary Gland ◽  
Pleomorphic Adenoma ◽  
Salivary Gland Neoplasm ◽  
Radical Cure ◽  
Large White ◽  
Case Presentation ◽  
The Right ◽  
Enhanced Computed Tomography ◽  
Histological Form

Abstract Background Paediatric cases of pleomorphic adenoma of the bronchus are rare in clinical practice, despite pleomorphic adenoma being the most common histological form of salivary gland neoplasm. To date, no such cases have been reported in China. Case presentation We report a case of pleomorphic adenoma of the bronchus in a 10-year-old child with no obvious positive signs on examination. Chest-enhanced computed tomography and bronchoscopy showed a large white mass in the right principal bronchus. The patient was treated by bronchial mass resection. Biopsy confirmed the diagnosis of pleomorphic adenoma. Conclusions We not only describe a rare benign bronchial tumour in children but also demonstrate the successful use of surgery as a radical cure for pleomorphic adenoma.

scholarly journals Atypical Presentation of Mammary Analogue Secretory Carcinoma of the Lip

2020 ◽  
pp. 014556132095775
Author(s):  
Abdulkader Yassin-Kassab ◽  
Danielle Gainor ◽  
Ahmed Saeed Sufyan
Keyword(s):  
Salivary Gland ◽  
Mucoepidermoid Carcinoma ◽  
Atypical Presentation ◽  
Rare Tumor ◽  
Secretory Carcinoma ◽  
Carcinoma Of The Breast ◽  
Case Presentation ◽  
Mammary Analogue Secretory Carcinoma ◽  
Not Otherwise Specified ◽  
Low Incidence

Mammary analogue secretory carcinoma (MASC) of the salivary gland is a rare tumor that was first described by Skalova et al in 2010, and since then, only a few hundred cases have been reported in the literature. Prior to Skalova’s report, MASC was histologically misclassified as acinic cell carcinoma (ACC), pleomorphic adenoma, mucoepidermoid carcinoma, or adenocarcinoma, not otherwise specified. Mammary analogue secretory carcinoma has a low incidence rate overall, accounting for less than 0.3% of all salivary gland tumors. Histopathologic and cytogenic analysis of MASC is identical to secretory carcinoma of the breast, leading to the proposed name by Skalova. The purpose of this case presentation is to describe an atypical presentation of MASC, to compare this case with the classic description of MASC, and to contrast the various features of MASC to ACC in order to improve the accuracy of future diagnoses and help guide treatment.

scholarly journals Aquaporin 1, 3, and 5 Patterns in Salivary Gland Mucoepidermoid Carcinoma: Expression in Surgical Specimens and an In Vitro Pilot Study

2020 ◽  
Vol 21 (4) ◽  
pp. 1287 ◽  
Author(s):  
Mérin Barbara Stamboni ◽  
Ágatha Nagli de Mello Gomes ◽  
Milena Monteiro de Souza ◽  
Katia Klug Oliveira ◽  
Claudia Fabiana Joca Arruda ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Mucoepidermoid Carcinoma ◽  
Tumor Biology ◽  
Tumor Stroma ◽  
Cell Phenotype ◽  
Mucosal Cells ◽  
Aqp1 Expression ◽  
Salivary Gland Malignancy ◽  
Vitro Model

Salivary gland aquaporins (AQPs) are essential for the control of saliva production and maintenance of glandular structure. However, little is known of their role in salivary gland neoplasia. Salivary gland tumors comprise a heterogeneous group of lesions, featuring variable histological characteristics and diverse clinical behaviors. Mucoepidermoid carcinoma (MEC) is the most common salivary gland malignancy. The aim of this study was to evaluate the expression of AQP1, AQP3, and AQP5 in 24 MEC samples by immunohistochemistry. AQP1 expression was observed in vascular endothelium throughout the tumor stroma. AQP3 was expressed in epidermoid and mucosal cells and AQP5 was expressed in mucosal cells of MEC. These proteins were expressed in the human MEC cell line UH-HMC-3A. Cellular ultrastructural aspects were analyzed by electron microscopy to certificate the tumor cell phenotype. In summary, our results show that, despite the fact that these molecules are important for salivary gland physiology, they may not play a distinct role in tumorigenesis in MEC. Additionally, the in vitro model may offer new possibilities to further investigate mechanisms of these molecules in tumor biology and their real significance in prognosis and possible target therapies.

Chemotherapy for Salivary Gland Cancer

1986 ◽  
Vol 95 (2) ◽  
pp. 165-170 ◽  
Author(s):  
Michael J. Kaplan ◽  
Michael E. Johns ◽  
Robert W. Cantrell
Keyword(s):  
Salivary Gland ◽  
Mucoepidermoid Carcinoma ◽  
Overall Response Rate ◽  
Palliative Chemotherapy ◽  
Response Rate ◽  
Metastatic Cancer ◽  
Complete Response ◽  
Salivary Gland Cancer ◽  
Doxorubicin Hydrochloride ◽  
Duration Of Response

Because of the scarcity of such lesions, little is known about the efficacy of chemotherapy for advanced salivary gland cancers. Although surgery and irradiation are the mainstays of treatment, patients with recurrent tumors and those with unresectable or metastatic cancer are not candidates for this usual approach. Ten patients with recurrent, metastatic, or unresectable salivary gland tumors were treated with combination chemotherapy, primarily with cisplatin, doxorubicin hydrochloride (Adriamycin), and cyclophosphamide, or cisplatin with 5-fluorouracil. In patients whose tumors exhibited no response, second-line drugs were used. The overall response rate was 50%—with one complete response—but the duration of response was short. This report contributes to the growing data base that demonstrates definite chemosensitivity of these tumors. To date, 116 patients have been reviewed. Adenocarcinoma-like cancers respond best to cisplatin, doxorubicin hydrochloride, and 5-fluorouracil. Highgrade mucoepidermoid carcinoma may show a sensitivity similar to that of squamous cell carcinoma. Multi-institutional protocols need to be developed to assess the roles of adjuvant and palliative chemotherapy in the treatment of salivary gland cancer.

Sign in / Sign up

Export Citation Format

Share Document